 |
|
Question the Obvious
Tamar Nijsten, MD, PhD;
Ellen R. M. de Haas, MD;
Martino H. A. Neumann, MD, PhD
Arch Dermatol. 2007;143(11):1429-1432.
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
|
|
In the evaluation of therapies, the physician-based clinical model (eg, global assessment by a physician, change in affected body surface area, index scores, disease-free interval, and survival and recurrence rates) alone is no longer sufficient. In addition to traditional methods of evaluating disease, regulatory agencies now require the assessment of the patient-reported outcomes (PROs).1 These outcomes are pivotal in dermatology because most dermatological diseases are chronic, intermittent, nonfatal, and very visible; cause no permanent physical damage; and their disease activity cannot be measured using serological markers. Initially, PROs focused on inflammatory dermatoses, but they now also include noninflammatory diseases and (benign and malignant) neoplasms, which are associated with different and specific issues (to some extent).
IMPORTANCE OF PROs
Because nonmelanoma skin cancers (NMSCs) rarely metastasize and cause few symptoms and treatment is often local, interest in patients' . . . [Full Text of this Article]
HRQOL IN PATIENTS WITH SKIN CANCER
PREDICTORS OF HRQOL IMPROVEMENT
INTERPRETATION OF COMPARISONS
ADVANTAGES OF NEW TREATMENTS
SENSIBLE RESOURCE ALLOCATION
AUTHOR INFORMATION
RELATED ARTICLE
Predictors of Skin-Related Quality of Life After Treatment of Cutaneous Basal Cell Carcinoma and Squamous Cell Carcinoma
Tina Chen, Daniel Bertenthal, Anju Sahay, Saunak Sen, and Mary-Margaret Chren
Arch Dermatol. 2007;143(11):1386-1392.
ABSTRACT
| FULL TEXT
|
